176 related articles for article (PubMed ID: 21476016)
1. Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results.
Gill H; Chim CS; Au WY; Loong F; Tse E; Leung AY; Kwong YL
Ann Hematol; 2011 Dec; 90(12):1399-407. PubMed ID: 21476016
[TBL] [Abstract][Full Text] [Related]
2. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Suh C; Kim HJ
Cancer Sci; 2010 Nov; 101(11):2443-7. PubMed ID: 20831770
[TBL] [Abstract][Full Text] [Related]
3. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
4. [Marginal zone lymphoma with monoclonal immunoglobulin: three cases report and literatures review].
Wang F; Han X; Bai B; Wang C; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):39-44. PubMed ID: 26876252
[TBL] [Abstract][Full Text] [Related]
5. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
[TBL] [Abstract][Full Text] [Related]
6. Marginal Zone Lymphoma: State-of-the-Art Treatment.
Sindel A; Al-Juhaishi T; Yazbeck V
Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
8. [Splenic marginal zone B-cell lymphoma with epidermotropic skin involvement].
Gómez-de la Fuente E; Villalón LB; Calzado-Villarreal L; Pinedo-Moraleda F; López-Estebaranz JL
Actas Dermosifiliogr; 2012 Jun; 103(5):427-31. PubMed ID: 21885023
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.
Teckie S; Qi S; Chelius M; Lovie S; Hsu M; Noy A; Portlock C; Yahalom J
Ann Oncol; 2017 May; 28(5):1064-1069. PubMed ID: 28327924
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
11. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project.
Nathwani BN; Anderson JR; Armitage JO; Cavalli F; Diebold J; Drachenberg MR; Harris NL; MacLennan KA; Müller-Hermelink HK; Ullrich FA; Weisenburger DD
J Clin Oncol; 1999 Aug; 17(8):2486-92. PubMed ID: 10561313
[TBL] [Abstract][Full Text] [Related]
12. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases.
Oh SY; Ryoo BY; Kim WS; Park YH; Kim K; Kim HJ; Kwon JM; Lee J; Ko YH; Ahn YC; Oh SJ; Lee SI; Kim HJ; Kwon HC; Bang SM; Kim JH; Park J; Lee SS; Kim HY; Park K
Am J Hematol; 2007 Jun; 82(6):446-52. PubMed ID: 17266060
[TBL] [Abstract][Full Text] [Related]
13. Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL).
Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Lee SI; Kang HJ; Choi CW; Park J; Song MK; Kim HJ; Kwon JH; Kwak JY; Bae SH; Park BB; Do YR; Lee HS; Jeong SH; Suh C; Kim HJ
Int J Hematol; 2012 Nov; 96(5):631-7. PubMed ID: 23065471
[TBL] [Abstract][Full Text] [Related]
14. Clinical presentation and management of marginal zone lymphomas.
Thieblemont C
Hematology Am Soc Hematol Educ Program; 2005; ():307-13. PubMed ID: 16304396
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients.
Heilgeist A; McClanahan F; Ho AD; Witzens-Harig M
Cancer; 2013 Jan; 119(1):99-106. PubMed ID: 22736411
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
Brown JR; Friedberg JW; Feng Y; Scofield S; Phillips K; Dal Cin P; Joyce R; Takvorian RW; Fisher DC; Fisher RI; Liesveld J; Marquis D; Neuberg D; Freedman AS
Br J Haematol; 2009 Jun; 145(6):741-8. PubMed ID: 19344412
[TBL] [Abstract][Full Text] [Related]
17. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
Avivi I; Arcaini L; Ferretti VV; Boumendil A; Finel H; Milone G; Zaja F; Liliana D; Musso M; Didier B; Bachy E; Wattad M; Nicolas-Virelizier E; Gramatzki M; Bourhis JH; Caillot D; Haenel A; Held G; Thieblemont C; Jindra P; Pohlreich D; Guilhot F; Kroschinsky F; Wahlin B; Scheid C; Ifrah N; Berthou C; Dreger P; Montoto S; Conconi A
Br J Haematol; 2018 Sep; 182(6):807-815. PubMed ID: 29984825
[TBL] [Abstract][Full Text] [Related]
18. Primary gastric non-Hodgkin's lymphoma in Chinese patients: clinical characteristics and prognostic factors.
Huang J; Jiang W; Xu R; Huang H; Lv Y; Xia Z; Sun X; Guan Z; Lin T; Li Z
BMC Cancer; 2010 Jul; 10():358. PubMed ID: 20604963
[TBL] [Abstract][Full Text] [Related]
19. Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites.
Kuper-Hommel MJ; van de Schans SA; Vreugdenhil G; van Krieken JH; Coebergh JW
Leuk Lymphoma; 2013 Sep; 54(9):1891-7. PubMed ID: 23302044
[TBL] [Abstract][Full Text] [Related]
20. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
